These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 27565935

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, Kim KH.
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [Abstract] [Full Text] [Related]

  • 5. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [Abstract] [Full Text] [Related]

  • 6. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM.
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [Abstract] [Full Text] [Related]

  • 7. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
    Hlaing AM, Furusato B, Udo E, Kitamura Y, Souda M, Masutani M, Fukuoka J.
    Biochem Biophys Res Commun; 2018 Sep 18; 503(4):2764-2769. PubMed ID: 30100056
    [Abstract] [Full Text] [Related]

  • 8. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Lung Cancer; 2017 Feb 18; 104():7-15. PubMed ID: 28213003
    [Abstract] [Full Text] [Related]

  • 9. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, Takemoto T, Mitsudomi T.
    Lung Cancer; 2016 Aug 18; 98():69-75. PubMed ID: 27393509
    [Abstract] [Full Text] [Related]

  • 10. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE, Abdelrahman AE, Abdelgawad M, Balata S, Shabrawy ME.
    Turk Patoloji Derg; 2017 Aug 18; 1(1):211-222. PubMed ID: 28832075
    [Abstract] [Full Text] [Related]

  • 11. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A, Zúñiga Á, Estors M, Martínez-Hernández NJ, Cremades A, Cuenca M, Galbis JM.
    Clin Lung Cancer; 2017 Mar 18; 18(2):e109-e116. PubMed ID: 27816393
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P, Lorenzo M, Menéndez S, Salido M, Albanell J, Pijuan L, Arriola E.
    Clin Lung Cancer; 2017 Nov 18; 18(6):682-691.e5. PubMed ID: 28549836
    [Abstract] [Full Text] [Related]

  • 13. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT, Bremnes RM, Donnem T.
    Clin Lung Cancer; 2017 Mar 18; 18(2):220-233.e8. PubMed ID: 27816392
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D.
    Oncotarget; 2016 May 24; 7(21):30772-80. PubMed ID: 27120796
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y, Lo AWI, Wong A, Chen W, Wang Y, Lin L, Xu J.
    Oncotarget; 2017 May 02; 8(18):30175-30189. PubMed ID: 28404915
    [Abstract] [Full Text] [Related]

  • 16. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C, Che G, Zheng X, Qiu J, Xie Z, Cong Y, Pei X, Zhang H, Sun H, Ma H.
    J Cancer Res Clin Oncol; 2019 Nov 02; 145(11):2663-2674. PubMed ID: 31541338
    [Abstract] [Full Text] [Related]

  • 17. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR.
    J Thorac Oncol; 2019 Jan 02; 14(1):25-36. PubMed ID: 30253973
    [Abstract] [Full Text] [Related]

  • 18. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
    Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.
    Ann Surg Oncol; 2019 Jun 02; 26(6):1925-1933. PubMed ID: 30815803
    [Abstract] [Full Text] [Related]

  • 19. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y.
    Lung Cancer; 2017 Sep 02; 111():182-189. PubMed ID: 28838391
    [Abstract] [Full Text] [Related]

  • 20. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y, Liu Q, Chen Z, Wang Y, Yang W, Hu Y, Han W, Zeng H, Ma H, Dai J, Zhang H.
    J Exp Clin Cancer Res; 2019 May 14; 38(1):193. PubMed ID: 31088500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.